Navigation Links
BioMarin to Present at the Piper Jaffray Healthcare Conference
Date:11/25/2008

NOVATO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York City on Tuesday, December 2, 2008 at 2:30 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contacts:
     Investors                                    Media
     Eugenia Shen                                 Susan Berg
     BioMarin Pharmaceutical Inc.                 BioMarin Pharmaceutical Inc.
     (415) 506-6570                               (415) 506-6594

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
2. BioMarin to Present at the Credit Suisse Healthcare Conference
3. BioMarin Announces Third Quarter 2008 Financial Results
4. BioMarin Corrects Information Included in Bloomberg Article
5. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
6. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
7. BioMarin to Present at the Citi Biotech Day
8. BioMarin Announces Roll-Out of National PKU Registry
9. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Collins Stewart Growth Conference
11. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 ... ... surgeons at the 2016 annual meeting of the North American Spine Society ... for patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is ...
(Date:1/17/2017)... ... January 17, 2017 , ... Diagenode, ... recently announced a collaboration with the Heidelberg University Hospital and the German Cancer ... preparation, following the company’s successful launch of its CATS (Capture and Amplification ...
(Date:1/16/2017)... 16, 2017   Valentin A. Pavlov, PhD , ... president and CEO of The Feinstein Institute for ... of how the nervous system regulates the immune system, ... bioelectronic medicine devices to treat disease and injury. ... . The paper examines various studies which ...
(Date:1/14/2017)... ARLINGTON, Va. , Jan. 13, 2017  The ... following statement in response to FDA final guidance ... FDA for its continued leadership in emphasizing the importance ... members are keenly aware of the benefits biosimilars will ... costs.   Yet the portion of the ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
Breaking Biology News(10 mins):